Article

November 9, 2018

AJMC® in the Press, November 9, 2018

Author(s):

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

OBR Oncology’s Thursday daily newsfeed included an article from The American Journal of Managed Care^® (AJMC^®). The article, “Azar Announces Mandatory Oncology Payment Model is Coming,” covered the HHS secretary’s announcement that the administration will revisit mandatory models that it had previously scrapped in cardiac care and that the time had come for “exploring new and improved episode-based models in other areas, including radiation oncology.”

AJMC^®’s The Center for Biosimilars^®’ article “FDA Approves Coherus’ Pegfilgrastim Biosimilar, Udenyca” was highlighted in OBR Oncology's Monday daily newsfeed. The article reported that, after previous US regulatory setbacks, the manufacturer had gained approval for its biosimilar, referencing Neulasta, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia.

Related Videos

Related Content

October 4th 2019

The Long-term Social Value of Granulocyte Colony-Stimulating Factors

Alison Sexton Ward, PhD Mina Kabiri, PhD Aylin Yucel, PhD, MSc, MBA, MHSA, PharmD Alison R. Silverstein, MPH Emma van Eijndhoven, MS, MA Charles Bowers, MD Mark Bensink, PhD, MSc, MEd Dana Goldman, PhD

Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.

April 15th 2019

The Conundrum Of Antibacterial Use in Neutropenic Patients Undergoing Chemotherapy for Hematologic Malignancy or HSCT

Sanjeet Singh Dadwal, MD

Patients with hematologic malignancy who are undergoing chemotherapy or a conditioning regimen for hematopoietic stem cell transplant (HSCT) are at high risk of infection because of the severity and duration of neutropenia. Fever with neutropenia is a common presentation that suggests an infection leading to empiric antibacterial therapy. To prevent infection and thus the neutropenic fever, antibacterial prophylaxis, especially with fluoroquinolones, emerged as a common practice based on results of 2 randomized controlled trials published in 2005 that showed reduced incidence of fever and bacteremia despite lack of a mortality benefit.

Neutropenia Etiology Influences Resulting Hematologic Consequences

March 2nd 2019

Neutropenia Etiology Influences Resulting Hematologic Consequences

Jaime Rosenberg

Hematological consequences of severe chronic neutropenia vary based on the underlying etiology of the condition, according to a study abstract presented at the 60th American Society of Hematology Annual Meeting & Exposition.

Patients With mCRPC Have Lower Risk of Severe Neutropenia

February 27th 2019

Patients With mCRPC Have Lower Risk of Severe Neutropenia

Jaime Rosenberg

Patients with metastatic castration-resistant prostate cancer (mCRPC) have a lower risk of developing grade 3 or 4 neutropenia, likely due to less exposure to docetaxel.

Home Monitoring Device for Blood Cell, Neutrophil Counts Shows Positive Initial Results

February 22nd 2019

Home Monitoring Device for Blood Cell, Neutrophil Counts Shows Positive Initial Results

Jaime Rosenberg

Initial results of a study have found that white blood cell counts and absolute neutrophil counts, which are well-established predictors of risk of infections or febrile neutropenia, can be accurately measured with a finger stick drop of blood and point-of-care hematology results.

Multiday Corticosteroid Administration Delays Diagnosis, Treatment of Febrile Neutropenia

February 19th 2019

Multiday Corticosteroid Administration Delays Diagnosis, Treatment of Febrile Neutropenia

Jaime Rosenberg

Researchers have found that multiday corticosteroid administration during chemotherapy delays the diagnosis of and antimicrobial administration for febrile neutropenia.

Related Content

October 4th 2019

The Long-term Social Value of Granulocyte Colony-Stimulating Factors

Alison Sexton Ward, PhD Mina Kabiri, PhD Aylin Yucel, PhD, MSc, MBA, MHSA, PharmD Alison R. Silverstein, MPH Emma van Eijndhoven, MS, MA Charles Bowers, MD Mark Bensink, PhD, MSc, MEd Dana Goldman, PhD

Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.

April 15th 2019

The Conundrum Of Antibacterial Use in Neutropenic Patients Undergoing Chemotherapy for Hematologic Malignancy or HSCT

Sanjeet Singh Dadwal, MD

Patients with hematologic malignancy who are undergoing chemotherapy or a conditioning regimen for hematopoietic stem cell transplant (HSCT) are at high risk of infection because of the severity and duration of neutropenia. Fever with neutropenia is a common presentation that suggests an infection leading to empiric antibacterial therapy. To prevent infection and thus the neutropenic fever, antibacterial prophylaxis, especially with fluoroquinolones, emerged as a common practice based on results of 2 randomized controlled trials published in 2005 that showed reduced incidence of fever and bacteremia despite lack of a mortality benefit.

Neutropenia Etiology Influences Resulting Hematologic Consequences

March 2nd 2019

Neutropenia Etiology Influences Resulting Hematologic Consequences

Jaime Rosenberg

Hematological consequences of severe chronic neutropenia vary based on the underlying etiology of the condition, according to a study abstract presented at the 60th American Society of Hematology Annual Meeting & Exposition.

Patients With mCRPC Have Lower Risk of Severe Neutropenia

February 27th 2019

Patients With mCRPC Have Lower Risk of Severe Neutropenia

Jaime Rosenberg

Patients with metastatic castration-resistant prostate cancer (mCRPC) have a lower risk of developing grade 3 or 4 neutropenia, likely due to less exposure to docetaxel.

Home Monitoring Device for Blood Cell, Neutrophil Counts Shows Positive Initial Results

February 22nd 2019

Home Monitoring Device for Blood Cell, Neutrophil Counts Shows Positive Initial Results

Jaime Rosenberg

Initial results of a study have found that white blood cell counts and absolute neutrophil counts, which are well-established predictors of risk of infections or febrile neutropenia, can be accurately measured with a finger stick drop of blood and point-of-care hematology results.

Multiday Corticosteroid Administration Delays Diagnosis, Treatment of Febrile Neutropenia

February 19th 2019

Multiday Corticosteroid Administration Delays Diagnosis, Treatment of Febrile Neutropenia

Jaime Rosenberg

Researchers have found that multiday corticosteroid administration during chemotherapy delays the diagnosis of and antimicrobial administration for febrile neutropenia.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions